Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
El desarrollo de biomarcadores plasmáticos ha revolucionado el diagnóstico biológico de la enfermedad de Alzheimer (EA), al permitir una detección más temprana y menos invasiva de los procesos neuropatológicos subyacentes.
Why it matters
This review describes plasma biomarkers such as Aβ42/40, p-tau181, p-tau217, NfL, GFAP, and ApoE within the A/T/N framework for diagnosing and monitoring Alzheimer's disease. It discusses their potential for earlier, less invasive diagnosis and personalized medicine, but does not report a treatment or cure.
-
Alzheimer disease represents a major medical and social challenge owning to the complexity of its diagnosis, especially at the preclinical stage.
Why it matters
This review summarizes evidence that ophthalmic imaging and artificial intelligence can help detect Alzheimer's disease at preclinical stages, with reported diagnostic accuracy (AUC 0.9). It also notes limitations including variability of results, insufficient specificity, and the black-box nature of artificial intelligence, and it does not address treatment, cure, or prevention.
-
Objetivo: Objetivou-se sintetizar, em revisão narrativa, as evidências publicadas entre 2022–2025 sobre o potencial neuroprotetor dos análogos do GLP-1 na Doença de Alzheimer (DA).
Why it matters
This narrative review reports that in experimental studies, GLP-1 agonists cross the blood-brain barrier, reduce inflammation and oxidative stress, and lower p-tau and Aβ, while small human trials and cohorts suggest possible cognitive stabilization and favorable trends on brain imaging. The authors conclude there is pathophysiological plausibility and early clinical signals, but the human evidence comes from small studies and does not yet establish these drugs as an effective treatment for Alzheimer's disease.
-
La presente revisión bibliográfica analiza el papel de la genética clínica en el diagnóstico y pronóstico de la enfermedad de Alzheimer, con un énfasis especial en el contexto ecuatoriano.
Why it matters
This review examines how clinical genetics, including variants in APOE, APP, PSEN1, and PSEN2 and biomarkers in plasma and cerebrospinal fluid, can improve diagnosis and prognosis of Alzheimer's disease. It highlights substantial inequalities between developed and developing countries, noting that in Ecuador diagnosis still relies largely on neuropsychological tests and conventional imaging, delaying early detection.
-
27/100
BSA-polymer conjugates displayed enhanced resistance to proteolytic degradation.
Why it matters
This laboratory study used polymer chemistry to make amyloid-beta-degrading enzymes more stable and better able to avoid immune detection. It is early laboratory work and does not show any effect on Alzheimer's disease in people.
-
Introdução: O sequenciamento de nova geração (NGS) tem revolucionado a compreensão da doença de Alzheimer (DA), desvendando biomarcadores genéticos e transcriptômicos que aprimoram a estrutura ATN (beta-amiloide, Tau, neurodegeneração).
Why it matters
This narrative review describes how next-generation sequencing has identified genes such as APP, TREM2 and PLD3 and highlighted pathways related to inflammation, synaptic dysfunction and neurodegeneration in Alzheimer's disease. It notes that challenges such as data interpretation and protocol standardization limit clinical application, so no treatment or cure is presented.
-
RESUMO A Doença de Alzheimer (DA) é uma condição progressiva caracterizada pelo acúmulo de placas de beta-amiloide e emaranhados neurofibrilares de proteína tau, resultando em perda sináptica e morte neuronal.
Why it matters
This literature review reports that Alzheimer's treatment is moving beyond symptom-only therapies toward disease-modifying strategies. It notes that monoclonal antibody immunotherapies show potential to reduce amyloid plaques and slow cognitive decline but face challenges with adverse effects, and that metabolic and inflammatory modulation and non-drug interventions are also promising approaches.
-
Recent years have seen a large increase in research directed at AD immunotherapy.
Why it matters
This literature review covers the large increase in Alzheimer's immunotherapy research from 2020 to 2023, noting that lecanemab and aducanumab are already registered in the US, among other places. It states that more studies are expected to solve problems of qualifying patients into appropriate groups and to allow more reliable evaluation of the molecules under study.
-
A Doença de Alzheimer (DA) é uma enfermidade neurodegenerativa progressiva e a principal causa de demência em idosos, representando cerca de 60 a 70% dos casos.
Why it matters
This literature review examined how genetic and epigenetic factors contribute to Alzheimer's development and progression, focusing on potential biomarkers and therapeutic strategies. Both genetic inheritance and epigenetic mechanisms influenced by environmental and lifestyle factors are implicated.
-
27/100
Alzheimer's disease (AD) is a neurological condition that worsens over time and is characterised by tau tangles and amyloid plaques.
Why it matters
This review discusses CRISPR-Cas9 and newer editing approaches targeting genes such as APP, PSEN1, PSEN2 and APOE4, with preclinical evidence in cellular and animal models. It notes that clinical use is hampered by concerns about long-term safety, delivery efficiency and ethical issues, so no treatment or cure is yet established.
-
27/100
The research focuses on the use of biomarkers to diagnose Alzheimer’s disease (AD) in living individuals.
Why it matters
This review reports that plasma NEFL, GFAP and GDF15 were consistently linked with incident dementia and Alzheimer's, and that an individual with greater GFAP levels is 2.32 times likely to acquire dementia. It also notes that drugs such as donanemab and lecanemab may delay progression, but the review itself presents no new treatment or cure.
-
A progressive neurological disease, Alzheimer's disease (AD) is identified by cognitive decline and memory loss.
Why it matters
This Vision Transformer model classified MRI scans across four disease stages with 95% accuracy and a 96% F1-score, outperforming conventional CNNs. It is a diagnostic tool and does not report any treatment, cure, or prevention of Alzheimer's disease.
-
La Agencia Europea de Medicamentos (EMA), tras realizar su comité CHMP una nueva evaluación de su dictamen inicial negativo en julio 2024, ha recomendado que se otorgue una autorización de comercialización limitada a pacientes de Alzheimer, que tienen una o ninguna copia de ApoE4, una determinada forma del gen de la proteína apolipoproteína E. Esta población tiene menos probabilidades de experimentar anomalías de imagen relacionadas con el amiloide (ARIA), una reacción adversa grave conocida, que implica edema (hinchazón) y posibles hemorragias cerebrales.
Why it matters
European regulators recommended a limited marketing authorization for lecanemab only in Alzheimer's patients who have one or no copies of the ApoE4 gene. This population is less likely to experience ARIA, a serious adverse reaction involving brain swelling and possible bleeding, which limits the drug's use.
-
Alzheimer's disease (AD) is the most common type of dementia and represents a significant global health problem due to its profound impact on patients' quality of life and the heavy burden it places on health care.
Why it matters
This systematic review explores the role of artificial intelligence in diagnosing and managing Alzheimer's disease. It summarizes existing work and does not itself test a treatment, cure or prevention.
-
A Doença de Alzheimer (DA) é a principal causa de demência em idosos, causada pelo acúmulo de β-amiloide e emaranhados neurofibrilares no cérebro.
Why it matters
This review of 6 studies found that blood biomarkers such as p-tau and β-amyloid are important for early diagnosis and monitoring of Alzheimer's disease, and that algorithms using markers like GFAP and YKL-40 may reduce the need for invasive procedures. The authors note ethical challenges remain and more research is needed before these biomarkers can be used in routine clinical practice.
-
A Doença de Alzheimer (DA) é uma condição neurodegenerativa caracterizada pela formação de placas de β-amiloide (Aβ) e emaranhados neurofibrilares no cérebro, resultando em um declínio cognitivo progressivo.
Why it matters
This review of six systematic reviews found that although anti-amyloid antibodies such as aducanumab, lecanemab and donanemab improved scores on cognitive scales like ADAS-Cog and MMSE in clinical trials, the effects did not reach a level of significant clinical relevance. The authors expect that future combinations of treatments and biomarkers may improve Alzheimer's management more effectively.
-
Yearly costs of evolocumab were $6,840. Donanemab was more expensive at $32,000.
Why it matters
This cost analysis reports that donanemab costs $32,000 yearly, higher than evolocumab at $6,840 but reasonably priced compared with other drug classes. It concludes that considering longevity, overall worldwide Alzheimer future management would be too costly to be affordable.
-
Met de registratie van lecanemab in april 2025 en donanemab in september 2025 komt slechts voor een klein deel van de patiënten in het beginstadium van de ziekte van Alzheimer een mogelijke therapie binnen bereik.
Why it matters
With the registration of lecanemab and donanemab, only a small proportion of patients in the early stage of Alzheimer's disease have a possible therapy within reach. The efficacy of both drugs is modest and there is a chance of complications from ARIA due to oedema or bleeding in the brain.
-
Progressive neurodegeneration, which causes memory loss, cognitive decline, and functional impairment is known as Alzheimer's disease, the most common type of dementia, first identified by Alois Alzheimer in 1907.
Why it matters
This review states that current pharmacological treatments for Alzheimer's disease provide only temporary relief and describes blarcamesine, a small-molecule sigma-1 receptor agonist and muscarinic receptor modulator, as a possible treatment option. It reports no confirmed cure or prevention.
-
This study proposes a deep learning-based framework to detect and classify Alzheimer's disease (AD) in the early stages using medical imaging, and specifically Magnetic Resonance Imaging (MRI).
Why it matters
This study used a convolutional neural network and a pre-trained MobileNet model to classify MRI scans for Alzheimer's disease, reporting 99.86% accuracy. The authors suggest the model could help clinicians diagnose Alzheimer's disease from MRI images, but it is a diagnostic tool and does not test any treatment, cure or prevention.
-
Various medicinal agents aimed at improving Alzheimer disease (AD) include cholinesterase inhibitors, memantine, aducanumab, and antioxidants.
Why it matters
This article summarizes acquired factors that influence risk for dementia, noting that medications such as cholinesterase inhibitors, memantine, aducanumab and antioxidants are typically prescribed once Alzheimer's disease is diagnosed to slow progression. It argues that significance should be placed on recognizing known acquired risk factors to potentially decrease the likelihood of developing dementia and perhaps specifically Alzheimer's disease.
-
The recent approval of aduhelm/aducanumab by the US Food and Drug Administration (FDA) in June 2021 raised hopes that further substances against Alzheimer's disease might be approved in the near future.
Why it matters
This paper evaluated the current status of phase III studies for Alzheimer's disease by searching clinicaltrials.gov on 7 August 2021 for studies targeting cognitive functions affected by the disease. It classified the mode of action of the different substances according to the Common Alzheimer's Disease Research Ontology.
-
Alzheimer's disease is a neurodegenerative disorder whose etiology continues to be discussed, to the point that there are different hypotheses that seek to clarify it, in addition to the fact that, given its multifactorial nature, there are different risk factors associated with its development.
Why it matters
This paper states that Alzheimer's etiology is still debated and that advances in molecule detection techniques now allow distinguishing healthy from diseased subjects at relatively early stages, though much remains to be done. It notes that aducanumab's marketing approval was questioned by the international medical community given controversial clinical trial results.
-
On June 7, 2021, the US Food and Drug Administration (FDA) approved aducanumab, a monoclonal amyloid targeting β-amyloid, for the treatment for Alzheimer's disease (AD).
Why it matters
This paper reports that the FDA approved aducanumab through the Accelerated Approval Pathway, essentially motivated by evidence that it reduces brain amyloid plaques. It notes that this news is causing heated debate in the scientific community, and that evidence of clinical benefit from two phase 3 trials is at issue.
-
27/100
Real-world, administrative claims data is uniquely suited to help characterize the journey of Alzheimer's disease (AD) patients from the onset of disease symptoms through diagnosis and beyond.
Why it matters
This analysis of Medicare claims found gaps and inconsistencies between when Alzheimer's disease was diagnosed and when treatment was recorded, with care-seeking often beginning before the first diagnosis code. It describes diagnostic and treatment patterns in claims data and does not test any treatment, cure, or prevention.
From across this topic
10 of the 5,172 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- The mechanical cause of age-related dementia (Alzheimer's disease): the brain is destroyed by the pulse
- Plasma Biomarkers of Alzheimer Disease in Women With and Without HIV
- Falls in people with Alzheimer’s disease: Exploring the role of inhibitory control
- Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE
- Genomics link obesity and type 2 diabetes to Alzheimers disease to unveil novel biological insights
- Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
- Microglia in Alzheimer's Disease: Exploring How Genetics and Phenotype Influence Risk
- Interactive effects of telomere length and genetic variants on Alzheimer disease risk across multiple ancestral populations
- A summary risk score for the prediction of Alzheimer disease in elderly persons
- Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials